Table 1 Modify the content in the Note of the table
Characteristics | Overall (N = 104) | ||
|---|---|---|---|
Age, years | 57.73 ± 12.56 | ||
Spectral CT interval, Day | 41.65 ± 6.88 | ||
Baseline CEA [median (IQR)] | 32.91 (17.00,96.40) | ||
Sex | |||
 Female | 44 (42.31%) | ||
Liver oligometastasis | |||
 YES | 33 (31.73%) | ||
 NO | 71 (68.27%) | ||
Type of liver metastasis | |||
 Synchronous | 44 (42.31%) | ||
 Metachronous | 60 (57.69%) | ||
 Baseline longest diameter, mm [median (IQR)] | 25.74 (20.55,30.18) | ||
 Spectral CT tumor longest diameter, mm [median (IQR)] | 26.22 (20.71,32.01) | ||
 6-month tumor longest diameter, mm [median (IQR)] | 32.63 (17.51,39.23) | ||
Sites of metastases | |||
 Liver only | 83 (79.81%) | ||
Liver and extrahepatic | Lung | 10 (9.62%) | |
Bone | 8 (7.69%) | ||
Others | 3 (2.88%) | ||
Systemic therapy scheme | |||
 FOLFIRI and bevacizumab | 72 (69.2%) | ||
 FOLFOX and bevacizumab | 32 (30.8%) | ||
Primary tumor | |||
 Rectum | 53 (51.0%) | ||
 Colon | 51 (49.0%) | ||
Histologic grade of the primary tumor | |||
 well/moderately differentiated | 49 (47.12%) | ||
 Others | 55 (52.88%) | ||
K-RAS | |||
 Wild | 49 (47.12%) | ||
 Mutant | 55 (52.88%) | ||
Clinical T stage of the primary tumor | |||
 T2 | 2 (1.92%) | ||
 T3 | 43 (41.35%) | ||
 T4 | 59 (56.73%) | ||
Clinical N stage of the primary tumor | |||
 N0-1 | 57 (54.8%) | ||
 N2 | 47 (45.2%) | ||
2-RECIST1.1 | |||
 R- | 98 (94.23%) | ||
 R +  | 6 (5.77%) | ||
6-RECIST1.1 | |||
 R- | 76 (73.08%) | ||
 R +  | 28 (26.92%) | ||
Outcomes | |||
 Alive | 12 (11.54%) | ||
 Overall survival, month [median (IQR)] | 24 (15.00,34.00) | ||